{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:18:03Z","timestamp":1775153883029,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00764","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T06:31:30Z","timestamp":1545114690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration"],"prefix":"10.3389","volume":"9","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concettina","family":"La Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Ruffilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Quattrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Piaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Patrizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Ulisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enke","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Materazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1258\/0022215054516197","article-title":"Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease","volume":"119","author":"O'Neill","year":"2005","journal-title":"J Laryngol Otol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann Surg Oncol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<64::AID-SSU10>3.0.CO;2-U","article-title":"Anaplastic thyroid carcinoma: a therapeutic challenge","volume":"16","author":"Ain","year":"1999","journal-title":"Semin Surg Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ecl.2008.02.003","article-title":"Anaplastic thyroid cancer","volume":"37","author":"Neff","year":"2008","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archsurg.133.1.89","article-title":"Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident","volume":"133","author":"Miccoli","year":"1998","journal-title":"Arch Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"De Crevoisier","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1089\/thy.2009.1599","article-title":"Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision","volume":"19","author":"Wartofsky","year":"2009","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11912-012-0217-0","article-title":"RET TKI: potential role in thyroid cancers","volume":"14","author":"Antonelli","year":"2012","journal-title":"Curr Oncol Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2002-021230","article-title":"The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells","volume":"88","author":"Podtcheko","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A6058","DOI":"10.1200\/jco.2009.27.15s.6058","article-title":"Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)","volume":"27","author":"Nagaiah","year":"2009","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1089\/105072502321085153","article-title":"Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors","volume":"12","author":"Dziba","year":"2002","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00280-005-0014-7","article-title":"Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes","volume":"57","author":"Straight","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1210\/en.2003-1228","article-title":"Effects of PTK787\/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study","volume":"145","author":"Schoenberger","year":"2004","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1089\/105072502320908286","article-title":"Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice","volume":"12","author":"Bauer","year":"2002","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/MLG.0b013e318031055e","article-title":"Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma","volume":"117","author":"Prichard","year":"2007","journal-title":"Laryngoscope"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.1158\/1078-0432.CCR-04-0690","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/sj.bjc.6602461","article-title":"Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines","volume":"92","author":"Nobuhara","year":"2005","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.1210\/jc.2011-1987","article-title":"CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"97","author":"Antonelli","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12020-015-0717-4","article-title":"CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation","volume":"53","author":"Fallahi","year":"2016","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"E572","DOI":"10.1210\/jc.2013-2321","article-title":"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo","volume":"99","author":"Antonelli","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","article-title":"Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3892\/or.2018.6306","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3892\/or.2018.6305","article-title":"Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","article-title":"Flasks, fibres and flanks\u2013pre-clinical tumour models for predicting clinical antitumour activity","volume":"84","author":"Newell","year":"2001","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000077984","article-title":"Is there a role for chemosensitivity tests in head and neck cancer?","volume":"27","author":"Dollner","year":"2004","journal-title":"Onkologie"},{"key":"B27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/0277-5379(90)90165-P","article-title":"Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer","volume":"26","author":"Schroyens","year":"1990","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1365-2265.2008.03415.x","article-title":"Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells","volume":"70","author":"Antonelli","year":"2009","journal-title":"Clin Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-08-0190","article-title":"Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration","volume":"159","author":"Antonelli","year":"2008","journal-title":"Eur J Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2265.2008.03182.x","article-title":"Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests","volume":"69","author":"Antonelli","year":"2008","journal-title":"Clin Endocrinol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/bjc.1996.258","article-title":"Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5\/SV40 hybrid virus","volume":"73","author":"Basolo","year":"1996","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1677\/ERC-08-0337","article-title":"Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"16","author":"Antonelli","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/DDDT.S93459","article-title":"Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives","volume":"10","author":"Costa","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer","volume":"21","author":"Nair","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B39","first-page":"695","article-title":"[Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer]","volume":"44","author":"Yamazaki","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"key":"B40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/thy.2016.0627","article-title":"Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer","volume":"27","author":"I\u00f1iguez-Ariza","year":"2017","journal-title":"Thyroid"},{"key":"B41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1530\/EDM-16-0136","article-title":"Efficacy of lenvatinib in a patient with anaplastic thyroid cancer","volume":"2017","author":"Oishi","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000457831","article-title":"Significant amelioration of tracheal stenosis following lenvatinib in a patient who has anaplastic thyroid carcinoma with bronchomediastinal infiltration: a case report","volume":"10","author":"Fukuhara","year":"2017","journal-title":"Case Rep Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for Anaplastic Thyroid Cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/BTT.S57619","article-title":"Multikinase inhibitors use in differentiated thyroid carcinoma","volume":"8","author":"Jasim","year":"2014","journal-title":"Biologics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1677\/ERC-06-0033","article-title":"A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis","volume":"14","author":"Johanson","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1060028013512791","article-title":"Vandetanib for the treatment of medullary thyroid carcinoma","volume":"48","author":"Cooper","year":"2014","journal-title":"Ann Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol."},{"key":"B49","unstructured":"Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY) [ClinicalTrials.gov Identifier: NCT01876784]2016"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-10-2762","article-title":"Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model","volume":"17","author":"Gule","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1021\/jm901785w","article-title":"Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation","volume":"53","author":"Taliani","year":"2010","journal-title":"J Med Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccr.2007.12.019","article-title":"Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape","volume":"13","author":"van Amerongen","year":"2008","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/ERC-09-0292","article-title":"The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells","volume":"18","author":"Vitagliano","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B57","doi-asserted-by":"publisher","first-page":"7664","DOI":"10.1158\/1078-0432.CCR-05-0455","article-title":"Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma","volume":"11","author":"Bravo","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000326884","article-title":"Needle track seeding of papillary thyroid carcinoma from fine needle aspiration biopsy. a case report","volume":"46","author":"Karwowski","year":"2002","journal-title":"Acta Cytol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00595-006-3331-5","article-title":"Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case","volume":"37","author":"Uchida","year":"2007","journal-title":"Surg Today"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T06:31:48Z","timestamp":1545114708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":59,"alternative-id":["10.3389\/fendo.2018.00764"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00764","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"article-number":"764"}}